Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer

review of the clinical evidence and consensus statement on appropriate use in the USA

Siamak Daneshmand, Anne K. Schuckman, Bernard H. Bochner, Michael S. Cookson, Tracy M. Downs, Leonard G. Gomella, H. Barton Grossman, Ashish M. Kamat, Badrinath R. Konety, Cheryl T. Lee, Kamal S. Pohar, Raj S. Pruthi, Matthew J. Resnick, Norm D. Smith, J. Alfred Witjes, Mark P. Schoenberg, Gary D. Steinberg

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Hexaminolevulinate (HAL) is a tumour photosensitizer that is used in combination with blue-light cystoscopy (BLC) as an adjunct to white-light cystoscopy (WLC) in the diagnosis and management of non-muscle-invasive bladder cancer (NMIBC). Since being licensed in Europe in 2005, HAL has been used in >200,000 procedures, with consistent evidence that it improves detection compared with WLC alone. Current data support an additional role in the reduction of recurrence of NMIBC. Since the approval of HAL by the FDA in 2010, experience of HAL-BLC in the USA continues to expand. To define areas of need and to identify the benefits of HAL-BLC in clinical practice, a focus group of expert urologists specializing in the management of patients with bladder cancer convened to review the clinical evidence, share their experiences and reach a consensus regarding the optimal use of HAL-BLC in the USA. The focus group concluded that HAL-BLC should be considered for initial assessment of NMIBC, surveillance for recurrent tumours, diagnosis in patients with positive urine cytology but negative WLC findings, and for tumour staging.

Original languageEnglish (US)
Pages (from-to)589-596
Number of pages8
JournalNature reviews. Urology
Volume11
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Cystoscopy
Urinary Bladder Neoplasms
Light
Focus Groups
Photosensitizing Agents
5-aminolevulinic acid hexyl ester
Neoplasm Staging
Cell Biology
Neoplasms
Urine
Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer : review of the clinical evidence and consensus statement on appropriate use in the USA. / Daneshmand, Siamak; Schuckman, Anne K.; Bochner, Bernard H.; Cookson, Michael S.; Downs, Tracy M.; Gomella, Leonard G.; Grossman, H. Barton; Kamat, Ashish M.; Konety, Badrinath R.; Lee, Cheryl T.; Pohar, Kamal S.; Pruthi, Raj S.; Resnick, Matthew J.; Smith, Norm D.; Witjes, J. Alfred; Schoenberg, Mark P.; Steinberg, Gary D.

In: Nature reviews. Urology, Vol. 11, No. 10, 01.10.2014, p. 589-596.

Research output: Contribution to journalReview article

Daneshmand, S, Schuckman, AK, Bochner, BH, Cookson, MS, Downs, TM, Gomella, LG, Grossman, HB, Kamat, AM, Konety, BR, Lee, CT, Pohar, KS, Pruthi, RS, Resnick, MJ, Smith, ND, Witjes, JA, Schoenberg, MP & Steinberg, GD 2014, 'Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA', Nature reviews. Urology, vol. 11, no. 10, pp. 589-596. https://doi.org/10.1038/nrurol.2014.245
Daneshmand, Siamak ; Schuckman, Anne K. ; Bochner, Bernard H. ; Cookson, Michael S. ; Downs, Tracy M. ; Gomella, Leonard G. ; Grossman, H. Barton ; Kamat, Ashish M. ; Konety, Badrinath R. ; Lee, Cheryl T. ; Pohar, Kamal S. ; Pruthi, Raj S. ; Resnick, Matthew J. ; Smith, Norm D. ; Witjes, J. Alfred ; Schoenberg, Mark P. ; Steinberg, Gary D. / Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer : review of the clinical evidence and consensus statement on appropriate use in the USA. In: Nature reviews. Urology. 2014 ; Vol. 11, No. 10. pp. 589-596.
@article{105d9faa3c56433f81cfdb8f14683f6b,
title = "Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA",
abstract = "Hexaminolevulinate (HAL) is a tumour photosensitizer that is used in combination with blue-light cystoscopy (BLC) as an adjunct to white-light cystoscopy (WLC) in the diagnosis and management of non-muscle-invasive bladder cancer (NMIBC). Since being licensed in Europe in 2005, HAL has been used in >200,000 procedures, with consistent evidence that it improves detection compared with WLC alone. Current data support an additional role in the reduction of recurrence of NMIBC. Since the approval of HAL by the FDA in 2010, experience of HAL-BLC in the USA continues to expand. To define areas of need and to identify the benefits of HAL-BLC in clinical practice, a focus group of expert urologists specializing in the management of patients with bladder cancer convened to review the clinical evidence, share their experiences and reach a consensus regarding the optimal use of HAL-BLC in the USA. The focus group concluded that HAL-BLC should be considered for initial assessment of NMIBC, surveillance for recurrent tumours, diagnosis in patients with positive urine cytology but negative WLC findings, and for tumour staging.",
author = "Siamak Daneshmand and Schuckman, {Anne K.} and Bochner, {Bernard H.} and Cookson, {Michael S.} and Downs, {Tracy M.} and Gomella, {Leonard G.} and Grossman, {H. Barton} and Kamat, {Ashish M.} and Konety, {Badrinath R.} and Lee, {Cheryl T.} and Pohar, {Kamal S.} and Pruthi, {Raj S.} and Resnick, {Matthew J.} and Smith, {Norm D.} and Witjes, {J. Alfred} and Schoenberg, {Mark P.} and Steinberg, {Gary D.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1038/nrurol.2014.245",
language = "English (US)",
volume = "11",
pages = "589--596",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer

T2 - review of the clinical evidence and consensus statement on appropriate use in the USA

AU - Daneshmand, Siamak

AU - Schuckman, Anne K.

AU - Bochner, Bernard H.

AU - Cookson, Michael S.

AU - Downs, Tracy M.

AU - Gomella, Leonard G.

AU - Grossman, H. Barton

AU - Kamat, Ashish M.

AU - Konety, Badrinath R.

AU - Lee, Cheryl T.

AU - Pohar, Kamal S.

AU - Pruthi, Raj S.

AU - Resnick, Matthew J.

AU - Smith, Norm D.

AU - Witjes, J. Alfred

AU - Schoenberg, Mark P.

AU - Steinberg, Gary D.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Hexaminolevulinate (HAL) is a tumour photosensitizer that is used in combination with blue-light cystoscopy (BLC) as an adjunct to white-light cystoscopy (WLC) in the diagnosis and management of non-muscle-invasive bladder cancer (NMIBC). Since being licensed in Europe in 2005, HAL has been used in >200,000 procedures, with consistent evidence that it improves detection compared with WLC alone. Current data support an additional role in the reduction of recurrence of NMIBC. Since the approval of HAL by the FDA in 2010, experience of HAL-BLC in the USA continues to expand. To define areas of need and to identify the benefits of HAL-BLC in clinical practice, a focus group of expert urologists specializing in the management of patients with bladder cancer convened to review the clinical evidence, share their experiences and reach a consensus regarding the optimal use of HAL-BLC in the USA. The focus group concluded that HAL-BLC should be considered for initial assessment of NMIBC, surveillance for recurrent tumours, diagnosis in patients with positive urine cytology but negative WLC findings, and for tumour staging.

AB - Hexaminolevulinate (HAL) is a tumour photosensitizer that is used in combination with blue-light cystoscopy (BLC) as an adjunct to white-light cystoscopy (WLC) in the diagnosis and management of non-muscle-invasive bladder cancer (NMIBC). Since being licensed in Europe in 2005, HAL has been used in >200,000 procedures, with consistent evidence that it improves detection compared with WLC alone. Current data support an additional role in the reduction of recurrence of NMIBC. Since the approval of HAL by the FDA in 2010, experience of HAL-BLC in the USA continues to expand. To define areas of need and to identify the benefits of HAL-BLC in clinical practice, a focus group of expert urologists specializing in the management of patients with bladder cancer convened to review the clinical evidence, share their experiences and reach a consensus regarding the optimal use of HAL-BLC in the USA. The focus group concluded that HAL-BLC should be considered for initial assessment of NMIBC, surveillance for recurrent tumours, diagnosis in patients with positive urine cytology but negative WLC findings, and for tumour staging.

UR - http://www.scopus.com/inward/record.url?scp=85027949194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027949194&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2014.245

DO - 10.1038/nrurol.2014.245

M3 - Review article

VL - 11

SP - 589

EP - 596

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 10

ER -